NeuroBo Pharma rises after safety review says MASH drug study can continue

MetaVia

13/03/2024 12:40

** Shares of drug developer NeuroBo Pharmaceuticals  NRBO.O 
rise 8% to $5.26 premarket
    ** NRBO says a safety review committee has recommended that
a mid-stage trial for co's experimental MASH drug can continue
without modification
    ** The recommendation is an early indication of the safety
of the drug, DA-1241 - CEO Hyung Heon Kim
    ** Metabolic dysfunction-associated steatohepatitis (MASH)
is a fatty liver disease that affects around 5% of the U.S.
population
    ** Up to last close, stock up 31.7% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))